| Hazard Information | Back Directory | [Uses]
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease[1]. | [in vivo]
Masavibart (ZRC3308-A7; 0.5, 2.5, 25 mg/kg; 48 h prior to the SARS-CoV-2 infection) effectively prevents SARS-CoV-2 infection in syrian hamster, when in combination with ZRC3308-B10 (ratio 1:1)[1].
Masavibart (0.5, 2.5, 25 mg/kg; i.p.; single) shows the serum levels remaines constant without much reduction for up to 7 days, in syrian hamster [1]. | Animal Model: | Female syrian hamster (7 to 10-week-old; SARS-CoV-2 infection model)[1]. | | Dosage: | 0.5, 2.5, 25 mg/kg | | Administration: | Intraperitoneal injection; 48 h prior to the SARS-CoV-2 infection | | Result: | Prevented SARS-CoV-2 infection when in combination with ZRC3308-B10. |
| [References]
[1] Yadav PD, et al. ZRC3308 Monoclonal Antibody Cocktail Shows Protective Efficacy in Syrian Hamsters against SARS-CoV-2 Infection. Viruses. 2021 Dec 3;13(12):2424. DOI:10.3390/v13122424 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|